🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Longevity enthusiasts want to create their own independent state. They’re eyeing Rhode Island.🌎 🔎Interviews by Laurence Ion VitaDAO 💛, Janine Leger Gitcoin, Max Unfried, Nathan S. Cheng thinks you should work on aging., Yuri Deigin, Patti Zettler & more... Jessica Hamzelou MIT Technology Review 🧪 🔗technologyreview.com/2023/05/31/107…

I really hard question for me; I changed my mind at least 3 times while thinking about this tweet (& have thought about this for decades). OTOH, at 71, a test predicting my mental state 25 years from now probably won't mean much to me!

#AdLaw geeks, Christina L. Boyd, Kent Barnett, and some random third co author of an article in the Vanderbilt Law Review would like a word... #LoperBrightAmicusTime (supremecourt.gov/DocketPDF/22/2…)

Compare papers.ssrn.com/sol3/papers.cf…

Bottom line: If we are worried about judicial neutrality in reviewing agency statutory interpretations, Chevron is your friend; a squishier standard like Skidmore or, worse, plenary de novo review will increase politics in judicial decisionmaking.

ISCT leaders Jacques Galipeau, Patti Zettler, Dan Weiss, Laertis Ikonomou at the University of Vermont's Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference. ISCT was delighted to participate and co-sponsor a session on the Compassionate Use of CGT

When AI is used in medicine, things will go wrong & patients will get hurt. (Just like without AI! Hopefully less!) Who should be liable? I. Glenn Cohen & I have thoughts at ssrn.com/abstract=45177…, forthcoming DePaul L Rev. Comments welcome! #MedicalAI #Tort #AI #HealthLaw

The (Judicially) Conservative Case for Keeping Chevron Deference, a short Yale Journal on Regulation post on my amici brief with Kent Barnett: yalejreg.com/nc/the-judicia…

Folks teaching FDA law - join us Fri for FDLI's faculty discussion reintegrating recent caselaw into your class. And oh boy, is there a lot of recent caselaw to contemplate! (*and* you don't need to be a FDLI member for this event) fdli.org/food-and-drug-…

It's not a Stanford Law School prize but from the American Board of Internal Medicine Foundation—much bigger deal! The article was with Stanford Med's Philip Pizzo & David Spiegel, published in JAMA. BIG congrats to all!

#FDA CBER Office of Therapeutic Products Town Hall: Nonclinical Assessment of Cell and Gene Therapy Products fda.gov/news-events/fd…

Great quotes! E.g.: "This is because the market for things that purport to improve people’s health and lives, like nutritional supplements, is huge . . .Almost none of them have been proven to any reasonable degree to do anything beyond lighten the consumer’s bank account"

Curious (or worried) about how #SCOTUS affirmative action decisions may hamper antiracist efforts in medicine? I’m grateful to Michigan Law Review for accepting “Antiracist Medicine in Colorblind Courts” for publication. Comments welcome! Draft: papers.ssrn.com/sol3/papers.cf… Abstract ⬇

Congratulations to @MicahLBerman, the new Stephen F. Loebs Professor in Health Services Management and Policy 👏! Berman is an international expert in tobacco policy and has a joint appointment at @OSU_Law. cph.osu.edu/news/2023/08/m…

"...if all of this effort were directed at coming up with more robust experiments, better treatments for sick people, or ways to make those treatments cheaper and more equitable. Instead, publishers, institutions, and academics are stuck in the cycle of following the money."

Lars Noah recently posted a critique of the FDA law scholars brief in the AHM v. FDA case abt mife’s regulation. Patti Zettler & I helped organize the amicus effort & were the lead amici. We disagree w many of Lars’s claims & wrote a short reply refuting them papers.ssrn.com/sol3/papers.cf…

As a person of color, religious minority & person with lived experience, I’m thrilled, honored, ecstatic to share that our (@jenndoliva) article, The ‘New’ Drug War, has been accepted for publication in the Virginia Law Review Virginia Law Review. I feel nothing but gratitude.

I'm very excited to participate in this George Mason Law Review symposium. Kent Barnett and I will be presenting a paper based on our amicus brief in this case (papers.ssrn.com/sol3/papers.cf…), which I guess means we'll be part of Chevron's defense team at this trial! 🤓

Yesterday, HHS made an official recommendation that marijuana be moved from Schedule I to Schedule III under federal law. To better understand what that could mean for marijuana, watch our recent event on cannabis scheduling, moderated by Cat Packer. youtu.be/Zt_HoRu527I?fe…